Validation of the Pig-a gene mutation assay has been based mainly on studies in male rodents. To determine if the mutagen-induced responses of the X-linked Pig-a gene differ in females compared to males, 7-or 14-week old male and female Sprague Dawley rats were exposed to N-ethyl-Nnitrosourea (ENU). In the study with the 7-week old rats, exposure was to 0, 1, 5 or 25 mg ENU/kg/ day for three consecutive days (study Days 1-3). Pig-a mutant phenotype reticulocyte (RET . The percentage of reticulocytes (%RET) was markedly higher in the 7-week old males compared to females through Day 15 (2.39-fold higher on Day −4). At 25 mg/ kg/day, ENU reduced Day 4 RET frequencies in both sexes, and the two highest dose levels resulted in elevated MN-RET frequencies, with no sex or treatment × sex interaction. The two highest dose levels significantly elevated the frequencies of mean RET CD59− and RBC CD59− in both sexes from Day 15 onward. RET CD59− and RBC CD59− frequencies were somewhat lower for females compared to males at the highest dose level studied, and differences in RET CD59− resulted in a statistically significant interaction effect of treatment × sex. In the study with 14-week old rats, treatment was for 3 days with 0 or 25 mg ENU/kg/day. RET frequencies differed to a lesser degree between the sexes, and in this case there was no evidence of a treatment × sex interaction. These results suggest that the slightly higher response in younger males than in the younger females may be related to differences in erythropoiesis function at that age. In conclusion, while some quantitative differences were noted, there were no qualitative differences in how males and females responded to a prototypical mutagen, and support the contention that both sexes are equally acceptable for Pig-a gene mutation studies.
Introduction
The X-linked phosphatidylinositol glycan-class A (Pig-a) gene has been used as a reporter for somatic cell mutation using flow cytometric analysis to determine whether cells of interest express glycosylphosphatidylinositol (GPI) anchored protein(s) on their cell surface (1) (2) (3) (4) . To date, rodent studies have primarily focused on erythrocytes, as relatively low volume blood samples can provide many millions of cells (5) . Flow cytometric analysis uses fluorescent antibodies against GPI-anchored cell surface markers, for instance CD59, to discriminate between wild-type and mutant phenotype cells. Interest in Pig-a assays for safety assessment has been high, in large part due to the ease with which the endpoints can be integrated into other studies, including repeat-dose toxicology studies (6) (7) (8) .
The in vivo Pig-a assay has been evaluated in international trials comprised of industry, regulatory agencies and academia, with important expertise and organisational support provided by the Health and Environmental Science Institute's Genetic Toxicology Technical Committee (HESI-GTTC) (9, 10) . The data generated to date indicate that, with proper training, the reproducibility and portability of erythrocyte-based assays are high (11, 12) . Furthermore, experience to date with reference genotoxicants indicate that flow cytometric analysis is capable of detecting treatment-related increases in the frequencies of mutant phenotype cells in the context of common study designs, including 28-day repeat dose rodent studies (6) (7) (8) 13, 14) .
An important feature of this mutagenesis assay is that the Pig-a gene is on the X chromosome, and because there is only one copy (or, in the case of females, one functional copy) of the X chromosome in each cell only a single inactivating mutation is required to cause expression of the mutant phenotype. This characteristic is critical because independent mutational events at each of two alleles would be too rare to serve as the basis of an efficient and easily scored assay. Although the process of lyonisation in the female leaves only one functional copy of the X chromosome, most of the validation work conducted to date has used male rats and data demonstrating that the mutagenic response in females is similar to that in males are scant. This led the 2013 International Workshops on Genotoxicity Testing (IWGT) Pig-a Workgroup to suggest that the scarcity of female-associated results is an important data gap that should be addressed. This Workgroup stated that: 'There is still a question of how test agent treatments, animal age, diet, etc. might affect the Pig-a mutant frequencies detected in females versus males. The Workgroup suggests conducting studies to evaluate any sex-related differences.' (15) .
To address this knowledge gap, we conducted the current studies to evaluate: (i) whether any sex-based differences would be observed for the primary endpoints associated with the Pig-a assay, (ii) the kinetics by which N-ethyl-N-nitrosourea (ENU)-induced mutant phenotype cells enter the peripheral blood circulation of female rats and (iii) whether any sex-based differences are influenced by animal age (7 versus 14 weeks). For comparative purposes, the frequency of micronucleated reticulocytes (MN-RET) was also determined. 
Materials and methods

Reagents
Animals, treatments and blood harvests
Experiments were conducted with the oversight of the University of Rochester's Institutional Animal Care and Use Committee. Male and female Sprague Dawley rats (Crl:SD) were purchased from Charles River Laboratories, Wilmington, MA. Rodents were allowed to acclimate for approximately 1 week before use. Water and food were available ad libitum throughout the acclimation and experimental periods. ENU solutions were prepared fresh each day of use, and were prepared in Phosphate Buffered Saline that had been adjusted to pH 6 with hydrochloric acid. Exposure was for three consecutive days at approximately 24 h intervals, and occurred via oral gavage in a volume of 10 ml per kg body weight.
For study no. 1, the age at the start of treatment was 7 weeks and rats were treated with 0, 2.5, 7.5 or 25 mg ENU/kg/day (n = 6 per dose level per sex). Blood samples were collected on Days −4, 4, 15, 29 and 46. For study no. 2, rats were treated at 14 weeks of age, and ENU exposure was at 0 or 25 mg/kg/day (n = 5 per dose level per sex). Blood samples were collected on Days −4, 15 and 38.
Collection of peripheral blood samples was performed by nicking a lateral tail vein with a surgical blade after animals were warmed briefly under a heat lamp. Approximately 100-200 µl of free-flowing blood were collected directly into heparinised capillary tubes (Fisher Scientific, CAT no. 22-260-950) per time point. For Pig-a analyses, 80 µl of each blood sample were transferred to tubes containing 100 µl kit-supplied heparin solution where they remained at room temperature for less than 2 h until leukodepletion (described in more detail below). For the MN-RET endpoint, 30 µl of each whole blood sample were transferred to tubes containing 100 µl kit-supplied heparin solution where they remained at room temperature for less than 2 h, after which they were fixed with ultracold methanol (16) .
As described previously, pre-treatment Pig-a mutant phenotype cell frequencies were used as study inclusion criteria (17) . Briefly, pre-treatment frequencies were compared to the distribution of 756 historical controls animals, and rats that exceeded a one-sided 95% upper tolerance interval, alpha 0.05, were considered outliers and excluded from the study (18) . Animals that did not exceed these threshold values (i.e. 2.86 RBC CD59-× 10 -6 total RBC and/or 2.97 RET CD59− × 10 -6 total RET) were randomised across treatment groups.
Micronucleated reticulocytes: sample preparation, data acquisition
Day 4 blood samples from study no. 1 were analysed for micronucleated reticulocyte (MN-RET) and reticulocyte (RET) frequencies via flow cytometry according to In Vivo Rat MicroFlow Kit manual instructions (v130712), procedures that have been described in detail elsewhere (16, 19) . The frequency of MN-RET was based on the acquisition of approximately 20,000 CD71-positive RET per blood sample. (Note that for this assay, RET are distinguished from mature erythrocytes based on anti-CD71-associated fluorescence.) Instrument setup and calibration was performed using kit-supplied biological standards (P. berghei-infected blood cells) (20) . A BD FACSCalibur™ flow cytometer running CellQuest™ Pro v5.2 software was used for data acquisition and analysis (Becton, Dickenson and Company, Franklin Lakes, NJ, USA).
Pig-a mutation: sample preparation, Data acquisition
With the exception of study no. 1 Day 4 specimens, every blood sample was analysed for Pig-a mutant cell phenotype frequencies. Pig-a analyses were in accordance with MutaFlow kit manual v1404003 instructions, and have been described previously (21, 22) . These experiments utilised the so-called 96 well plate-based method, whereby microtiter plates facilitated multisample/parallel labelling and washing procedures, as well as walk-away data acquisition through the use of a BD HTS instrument that automatically delivered well contents to the flow cytometer. As described previously, 'pre-column' samples consisted of a small aliquot of each fully labelled and stained sample which was analysed for 1 min in order to provide %RET measurements as well as RBC to Counting Bead and RET to Counting Bead ratios. (For this assay, RET are distinguished from mature erythrocytes based on RNA-associated staining.) The majority of each sample was then used for an immunomagnetic separation procedure, and the resulting 'postcolumn' eluates were analysed for 3 min to provide mutant phenotype RBC to Counting Bead and mutant phenotype RET to Counting Bead ratios. As described previously, pre-and post-column data were used to calculate mutant phenotype erythrocyte (RBC CD59−
) and mutant phenotype reticulocyte (RET CD59− ) frequencies (23) . For the current studies >1.5 × 10 6 RET and > 150 × 10 6 RBC equivalents per rat per time point were consistently scored.
An Instrument Calibration Standard was generated on each day data acquisition occurred. As approximately one half of these erythrocytes were not incubated with anti-CD59-PE, these samples contained a high prevalence of mutant-mimic cells and provided a means to define the location of GPI anchor-deficient erythrocytes (24) . A BD FACSCalibur flow cytometer running CellQuest Pro v6.1.3 software was used for these Pig-a analyses.
Calculations and statistical analyses
The incidence of RETs and MN-RET is expressed as frequency percent, while the incidence of mutant phenotype cells is expressed as number per 10 6 cells. All %RET, %MN-RET, mutant phenotype cell frequencies, averages and standard error calculations were performed with Excel Office X for Mac ® (Microsoft, Seattle, WA, USA). Prior to conducting parametric tests, MN-RET, RBC CD59− and RET CD59− frequencies were log(10) transformed to ensure a normal distribution. Since zero RET CD59− values were occasionally observed, a 0.1 offset was added to each RET CD59− value prior to log transformation.
Statistical tests were performed in JMP ® software for Mac, v8.01 (SAS Institute Inc., Cary, NC, USA). For all analyses, P < 0.5 was used to indicate a significant effect. In the case of pre-treatment weight, RET, RET CD59− and RBC CD59− values, the effect of Sex was evaluated with two-tailed Student's t-tests.
MN-RET and RET values associated with Day 4 specimens were evaluated for treatment, sex, and treatment × sex interaction effects using JMP software's two-way analysis of variance (ANOVA) platform. When treatment was identified as a significant factor that affected MN-RET, dose levels that were elevated relative to concurrent vehicle control were identified by a one-sided Dunnett's test. When treatment was identified as a significant factor that affected RET values, dose levels that differed from concurrent vehicle control were identified by a two-sided Dunnett's test. The post hoc tests considered males and females separately. RET CD59− , RBC CD59− and RET values associated with Day 15 and later time points were evaluated for treatment, sex and treatment × sex interaction effects using JMP's two-way ANOVA platform. For these analyses, each time point was considered separately. When treatment was identified as a significant factor, dose levels that caused elevated RET CD59− or RBC CD59− frequencies relative to concurrent controls were identified by a one-sided Dunnett's test. When treatment was found to affect %RET, the groups that exhibited significantly different values relative to concurrent controls were identified by a two-sided Dunnett's test, P < 0.05. The post hoc tests considered males and females separately.
Results and discussion
Study no. 1: seven-week old rats
Prior to dosing, males and females exhibited markedly different body weights and %RET, with males exhibiting 1.37-and 2.39-fold higher means, respectively (Figure 1a and b) . Females' spontaneous RET CD59− and RBC CD59− frequencies were similar to those exhibited by males (Figure 1c and d) . Note that the male and female blood cells exhibited qualitatively similar fluorescence profiles during flow cytometric analysis. See Figure 2 for representative female fluorescence plots, males not shown.
Summary statistics that describe the results of the micronucleus assay conducted on Day 4 blood samples are provided in Tables I  and II . As illustrated by Figure 3 , and consistent with pre-treatment analyses, females exhibited lower %RET compared to males. Both sexes showed a treatment-related reduction in %RET at the highest dose of ENU studied. MN-RET frequencies were elevated in the 5 and 25 mg ENU/kg/day treatment groups. Despite sex-related differences in basal erythropoiesis function as indicated by mean %RET values, the spontaneous and ENU-induced %MN-RET were similar in male and female rats.
Summary statistics that describe RET data associated with the Pig-a assay are provided in Table III . The corresponding data are presented graphically in Figures 4 and 5 , where it is apparent that Days 15 and 29 %RET data were influenced by sex, with males showing higher mean values. The sex effect was not evident on Day 46. In general, treatment did not affect %RET at these relatively late time points. One exception is that Day 15 showed significantly reduced %RET, but this was only evident in males at the lowest dose studied.
Summary statistics for RET CD59− analyses are provided in Table  IV . As shown by Figure 4 , male RET CD59− frequencies exhibited characteristic responses to short-term treatment with ENU-near maximal frequencies at Day 15, with similar frequencies evident weeks thereafter (11) . Robust and statistically significant effects were observed for the two highest dose levels tested, 5 and 25 mg/kg/day. Female rats showed similar kinetics, with maximal RET CD59− values on Day 15 and similar values observed through Day 46. Females exhibited modestly lower mean values in the high dose treatment group relative to males, an observation that was apparent at each of the post-treatment time points studied. This led to a significant treatment × sex interaction effect at two of the three time points studied-Days 15 and 46, P = 0.0481 and 0.0296, respectively.
Summary statistics for RBC CD59− analyses are provided in Table  V . As shown in Figure 5 , male ENU-induced RBC CD59− frequencies rose more slowly than RET CD59− , an expected result given the slower turnover rate of the total RBC pool (11) . Female rats exhibited similar kinetics, with maximal RBC CD59− values evident at Day 46. For both sexes, statistically significant effects were observed for the two highest dose levels tested, 5 and 25 mg/kg/day. In agreement with RET CD59− data, females in the high treatment group had modestly Pre-column analyses were only used to determine reticulocyte frequency, reticulocyte to Counting Bead ratio and total erythrocyte to Counting Bead ratio. Plots c and d are post-column samples from a vehicle control and ENU-treated female rat, respectively. These samples were depleted of wild-type erythrocytes via immunomagnetic separation. The number of mutant phenotype reticulocytes and mutant phenotype erythrocytes are directly determined from the post-column samples, while the number of total cell equivalents (the denominator) is determined from the pre-column sample. The fluorescence profiles shown here are indistinguishable from those exhibited by male rats (data not shown).
lower mean RBC CD59− values compared to like-treated males at each of the three time points studied. While RBC CD59− exhibited a significant sex-only effect at one time point (Day 15), there was no evidence of a treatment × sex interaction as there was with RET CD59− .
Study no. 2: 14-week old rats
A follow-up study was performed to investigate the modest treatment × sex interaction that was observed for mutant phenotype reticulocytes. For this experiment, 14-week old rats were exposed to 0 or 25 mg ENU/kg/day for 3 days. Based on the previous study's Day 46 data, we expected male and female rats of this age to exhibit similar %RET values, thereby representing a means to assess whether males' elevated erythropoiesis function might explain the previously observed treatment × sex interaction. In the second study, pretreatment blood samples showed a statistically significant difference in RET frequencies (P = 0.0017). Even so, the difference in mean %RET was small in absolute terms-2.4 ± 0.14% for females versus 3.10 ± 0.12% for males (mean ± SEM).
Summary statistics for %RET, RET CD59− and RBC CD59− analyses are provided in Tables VI-VIII. There were no statistically significant treatment × sex interaction effects noted in this experiment, although one time point (Day 15) showed a sex effect for the RBC CD59− endpoint. The robust ENU-induced effects on mutant phenotype cell frequencies are presented graphically in Figures 6 and 7 .
Conclusions
For some regulatory genetic toxicology tests, e.g. the erythrocytebased micronucleus assay, there has been a historical bias for studying males only when sex-related differences in metabolism, distribution and/or toxicity are not anticipated (25) .
There are several reasons why the practice of evaluating only males in the Pig-a assay (and other genetic toxicology assays) should be reconsidered. The convention to study males only in genetic toxicology was developed at a time when genetic assays/endpoints were studied in isolation-that is, they were dedicated studies that assessed one endpoint of DNA damage. In that environment, a requirement to study both sexes would have increased the number of rodents tested, something the 3Rs philosophy tries to avoid when possible. Newer evidence as well as regulatory advice promote the merits of combining genetic toxicology endpoints into one study, and for integrating these endpoint(s) into other ongoing experiments, for instance repeatdose general toxicology studies (6) (7) (8) 13, 14) . The Pig-a assay has been shown to be well suited for integrated studies, and general toxicology studies typically do include males and females. Thus, in these circumstances, the number of animals available for studying Pig-a mutation would not be increased through the inclusion of female rodents because both sexes are evaluated routinely in toxicology studies. Integration therefore provides an opportunity to improve the statistical power of the assay and to consider potential sex-related differences in response to treatment without increasing the number of animals in a study. This is reinforced by recent recommendations of the National Institutes of Health, an agency that has articulated the need for preclinical studies to move away from a convention of males only, and to conduct in vivo toxicology and other studies with both sexes (26) . The results presented herein support the compatibility of female rats with Pig-a gene mutation analyses. Although erythropoiesis function is lower in young females compared to young males, this did not affect baseline mutant phenotype cell frequencies and did not appreciably reduce the sensitivity of the assay. In somewhat older rats (14 weeks) %RET values were much closer for the two sexes and in this case no treatment × sex interaction was observed. One possible explanation for the differences observed in these two studies is that erythropoiesis may have a small effect on genotoxicant-induced mutant yield, particularly in young males where a higher level of hematopoiesis is observed compared to young females or older males and females. It is noteworthy that the report of Kenyon and colleagues in this same Special Topic Issue of Mutagenesis (27) shows that Wistar-Han rats treated with a non-genotoxic hemolytic agent showed no effect on Pig-a mutant phenotype cell frequencies despite a strong compensatory erythropoiesis effect, which is consistent with the negligible effect of erythropoiesis function on the spontaneous mutant frequency in this study.
In conclusion, these results indicate that male and female animals are equally suitable for use in Pig-a assay. The results show slight quantitative differences that may be due to the difference in erythropoiesis as opposed to a genetic difference related to the lyonisation process. Thus, integrated study designs would benefit from Pig-a measurements in both sexes when they are available in the underlying study. This would represent a convenient and cost-effective way to identify potential sex differences in the mutagenic activation, internal exposure to the active form, or repair of DNA lesions, as well as providing improvements to statistical power. Further comparative studies of male versus female responses to different classes of mutagenic agents are warranted. In the meantime there continues to be merit to monitoring and reporting erythropoiesis function (e.g. by routinely monitoring the reticulocyte frequency) during the conduct of Pig-a assays.
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